information may not be available.
For many populations, such as the three examples above, no sampling frame exists, so that it may be impossible to obtain a representative sample. Consider, for example, trying to select a random sample of all the preschool children in an area to estimate the prevalence of vision or hearing defects. Yet for studies such as this, which set out to estimate the prevalence or incidence of some condition, the need for a truly representative sample is particularly great-otherwise the results are of uncertain value.
Even with a good selection procedure the study may be ruined by a poor response rate. Although deemed non-invasive, such studies may entail visiting people at home, expecting them to complete and return a questionnaire, or to attend a clinic, and thus may be liable to considerable non-cooperation.
Unfortunately, those who do not participate often tend to be somewhat different from those who do, both in respect of their medical condition (if this is relevant) and their social and demographic characteristics. This problem should be anticipated at the design stage, and plans made to "chase up" nonresponders. It is generally advisable to keep questionnaires and other procedures short and simple to help reduce non-response. In the end, though, the response rate may largely depend on the subjects' perception of the importance of the study.
It is much less common in case-control studies to find researchers concerned about defining the subjects who will be eligible for a study, although Sackett' has described 22 biases that may arise at this stage. One of the most interesting is Berkson's bias, which Mainland2 recently drew to the attention of readers of this journal. Case-control studies of hospital patients are often set up to study the relation between a specific disease and exposure to a suspected causal factor. If the hospital admission rates for exposed and unexposed cases and controls differ appreciably, then the observed association between the factor and the disease may be seriously biased (in either direction).2 Indeed, the choice of control group may affect the observed association between a disease and a suspected cause. A consequence of this is that such studies may need to be supported by prospective studies.
Another of Sackett's catalogue' is the membership (or "selfselection") bias. He cites the example of an apparent association between lack of exercise after myocardial infarction and the increased risk of recurrent attacks. This result was found in two observational studies where exercise was taken voluntarily, but was not substantiated by a prospective randomised study.
So the major problem of all observational studies is the selection of subjects for study. This aspect must be given con The use of historical controls is often advocated as being more ethical than using a concurrent randomised control group. The results of studies using historical controls are extremely unreliable, however, so that unless there is sound justification for their use such designs should themselves be rejected as unethical.
ADAPTIVE DESIGNS
Designs where the proportion of subjects allocated to each treatment depends on the accumulated results so far may appear preferable to randomised trials.7 It must be realised, however, that with such designs some subjects are still allocated to the treatment that is less successful so far, not so many as with randomised studies but still essentially at random. Furthermore, because of the unequal sample sizes for the two treatments, the study may require more subjects than an equal allocation study.'13 Such designs require that the result for each individual is known quickly, which is often not the case. It is implicitly assumed that there is a single outcome of interest, whereas there may be several possible methods of assessment, as well as aspects such as side effects to be considered. They are also insensitive to any secular changes during the course of the study. For these reasons, although appealing in principle, adaptive designs have rarely, if ever, been used.' SEQUENTIAL DESIGNS Sequential designs'4 may seem the best compromise in that they combine the many advantages of a randomised study with the desirable feature of taking account of the results so far in determining the length of the trial.
The main advantage over an ordinary randomised study is that the required sample size will be smaller if the treatment "effect" is larger. So the bigger the difference between treatments, the fewer subjects receive the less successful treatment.
Their main disadvantages are the same as for adaptive designs, especially the need for the results for each subject to be available quickly. Sequential designs are clearly of no value in long-term studies, where all the subjects will be recruited before any results are obtained. Nevertheless, in the right circumstances they can be useful and should probably be used more often.
CONSENT
Another problem of clinical trials is the need to obtain the "informed consent" of the subjects. In some cases this may be impossible because of the age or condition of the subjects, or because of the difficulty of explaining the scientific issues. Zelen This design, which seems perfectly ethical (Zelen"5 discusses many of the issues), has two advantages over ordinary randomised trials-the ability to include all eligible subjects and the avoidance of the tricky problem of informed consent.
PLACEBOS
Too many studies compare a new treatment with a placebo rather than an existing treatment, and thus yield results that are of no practical importance. It is sometimes necessary to include placebos, but whenever possible they should be used only when there is no appropriate treatment for comparison. Invasive placebo treatment is unlikely ever to be justified.
CONCLUSIONS
There is no one best design for all clinical trials. The choice for a specific trial must depend on the seriousness of the condition being treated, the nature of the treatments, the response time, the measures of outcome, and so on. The main ethical problem is balancing the interests of the individuals in the study with those of the much larger number who may benefit in the long term. But it is also vital that the research should provide useful results, and this may often be achieved best by a randomised study (double-blind if possible). If it is thought likely that highly favourable early results or a high incidence of side effects would argue in favour of premature termination of the study, then these considerations may be built in, using a sequential design.
The ethical difficulties associated with the widespread use of a new treatment without a trial are far greater than those associated with the trial itself. No barium studies were done, but endoscopy showed a stricture of the middle third of the oesophagus. The cause could not be determined, but when dilatation was attempted (Eder-Puestow technique) the oesophagus was perforated. The patient was transferred to our unit and the underlying pathology was unknown.
A Gastrografin swallow failed to outline the oesophagus, all the contrast medium having passed directly into the pleural cavity. Because of the possibility of a benign stricture thoracotomy was performed, but an unresectable carcinoma of the middle third of the oesophagus was discovered. Despite palliative intubation the patient died. Had a radiological diagnosis been made on this patient first a useless and painful thoracotomy could have been avoided.
Case 2-A woman aged 68 presented with retrosternal discomfort and vomiting. Her general practitioner had requested that barium studies be arranged. Instead, endoscopy was performed and a possible paraoesophageal hernia diagnosed.
